Motif (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics was notified, on 2 October 2015 that Dr. John Stakes, Non Executive Director of Motif, purchased 100,000 ordinary shares in the Company at 60 pence per ordinary share on 2 October 2015. Accordingly, Dr. John Stakes owns 171,850 ordinary shares, representing approximately 0.16 per cent of the Company’s issued share capital.
Motif Bio plc
Graham Lumsden, Chief Executive Officer
Robert Bertoldi, Chief Financial Officer
Zeus Capital Limited (Nominated Advisor and Broker)
Phil Walker / John Treacey
+44 (0) 207 533 7727
Northland Capital Partners (Broker)
Patrick Claridge / David Hignell
John Howes / Mark Treharne (Broking)
+44 (0) 207 382 1100
MC Services AG (Trade PR)
+49 (0) 89 210 2280
+44 (0) 207 148 5998
Plumtree Capital Limited (Financial Advisor)
+44 (0) 207 183 2493
Yellow Jersey PR (Financial PR)
+44 (0) 7768 537 739
Notes to Editors
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.